{"title":"SSRI药物对高血压和抑郁症患者心率和血压的影响。","authors":"M F Peixoto, Mlr Cesaretti, S D Hood, A Tavares","doi":"10.1080/10641963.2018.1501058","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To test the role of escitalopram on blood pressure and heart rate of individuals with hypertension and depression.</p><p><strong>Methods: </strong>A total of 30 individuals participated in this study who were being treated for hypertension and were diagnosed with major depression. Escitalopram (10-20 mg) was administered to 15 individuals, while the other 15 received placebo. These individuals were followed for 8 weeks with regular monitoring of blood pressure and heart rate. Scores on the Hamilton Depression Rating Scale were evaluated within the first, second, fourth, and eighth weeks of the study onset.</p><p><strong>Results: </strong>Comparing with placebo, heart rate was lower in the escitalopram group (66.79 ± 9.85 vs. 74.10 ± 9.52 bpm, p = 0.044). There was not a significant decrease of systolic blood pressure (140.80 ± 16.48 vs 139.61 ± 18.92 mmHg, p = 0.85) and diastolic blood pressure (80.55 ± 12.64 vs 80.18 ± 16.36 mmHg, p = 0.94).</p><p><strong>Conclusion: </strong>Escitalopram decreases HR, but not BP, in individuals with hypertension and depression. Abbreviation: SH: systemic hypertension; BP: blood pressure; DSM: Diagnostic and Statistical Manual of Mental Disorders; SRQ 20: Self-Report Questionnaire; SCID: Structured Clinical Interview for DSM-IV; HR: heart rate; SNS: Sympathetic nervous system; HPA: hypothalamus-pituitary-adrenal axis; RAA: renin, angiotensin, aldosterone system; NE: norepinephrine; CSF: cerebrospinal fluid; HAM-D: Hamilton Depression Rating Scale; CRF: corticotropin releasing factor; ACTH: adrenocorticotropic hormone; BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; t: time.</p>","PeriodicalId":286988,"journal":{"name":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","volume":" ","pages":"428-433"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/10641963.2018.1501058","citationCount":"8","resultStr":"{\"title\":\"Effects of SSRI medication on heart rate and blood pressure in individuals with hypertension and depression.\",\"authors\":\"M F Peixoto, Mlr Cesaretti, S D Hood, A Tavares\",\"doi\":\"10.1080/10641963.2018.1501058\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To test the role of escitalopram on blood pressure and heart rate of individuals with hypertension and depression.</p><p><strong>Methods: </strong>A total of 30 individuals participated in this study who were being treated for hypertension and were diagnosed with major depression. Escitalopram (10-20 mg) was administered to 15 individuals, while the other 15 received placebo. These individuals were followed for 8 weeks with regular monitoring of blood pressure and heart rate. Scores on the Hamilton Depression Rating Scale were evaluated within the first, second, fourth, and eighth weeks of the study onset.</p><p><strong>Results: </strong>Comparing with placebo, heart rate was lower in the escitalopram group (66.79 ± 9.85 vs. 74.10 ± 9.52 bpm, p = 0.044). There was not a significant decrease of systolic blood pressure (140.80 ± 16.48 vs 139.61 ± 18.92 mmHg, p = 0.85) and diastolic blood pressure (80.55 ± 12.64 vs 80.18 ± 16.36 mmHg, p = 0.94).</p><p><strong>Conclusion: </strong>Escitalopram decreases HR, but not BP, in individuals with hypertension and depression. Abbreviation: SH: systemic hypertension; BP: blood pressure; DSM: Diagnostic and Statistical Manual of Mental Disorders; SRQ 20: Self-Report Questionnaire; SCID: Structured Clinical Interview for DSM-IV; HR: heart rate; SNS: Sympathetic nervous system; HPA: hypothalamus-pituitary-adrenal axis; RAA: renin, angiotensin, aldosterone system; NE: norepinephrine; CSF: cerebrospinal fluid; HAM-D: Hamilton Depression Rating Scale; CRF: corticotropin releasing factor; ACTH: adrenocorticotropic hormone; BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; t: time.</p>\",\"PeriodicalId\":286988,\"journal\":{\"name\":\"Clinical and Experimental Hypertension (New York, N.y. : 1993)\",\"volume\":\" \",\"pages\":\"428-433\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/10641963.2018.1501058\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Hypertension (New York, N.y. : 1993)\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10641963.2018.1501058\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/7/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10641963.2018.1501058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/7/26 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8
摘要
目的:探讨艾司西酞普兰对高血压合并抑郁症患者血压和心率的影响。方法:共有30名正在接受高血压治疗并被诊断为重度抑郁症的个体参与了这项研究。15人服用艾司西酞普兰(10-20毫克),另外15人服用安慰剂。这些人被跟踪了8周,定期监测血压和心率。在研究开始的第一、第二、第四和第八周内评估汉密尔顿抑郁评定量表的得分。结果:与安慰剂组比较,艾司西酞普兰组心率(66.79±9.85比74.10±9.52 bpm, p = 0.044)明显降低。收缩压(140.80±16.48 vs 139.61±18.92 mmHg, p = 0.85)和舒张压(80.55±12.64 vs 80.18±16.36 mmHg, p = 0.94)无显著降低。结论:艾司西酞普兰可降低高血压合并抑郁症患者的HR,但不能降低血压。缩写:SH:全身性高血压;BP:血压;精神疾病诊断与统计手册;srq20:自我报告问卷;SCID: DSM-IV的结构化临床访谈;HR:心率;SNS:交感神经系统;HPA:下丘脑-垂体-肾上腺轴;RAA:肾素、血管紧张素、醛固酮系统;东北:去甲肾上腺素;CSF:脑脊液;汉密顿抑郁评定量表;促肾上腺皮质激素释放因子;促肾上腺皮质激素;BMI:身体质量指数;SBP:收缩压;DBP:舒张压;t:时间。
Effects of SSRI medication on heart rate and blood pressure in individuals with hypertension and depression.
Objective: To test the role of escitalopram on blood pressure and heart rate of individuals with hypertension and depression.
Methods: A total of 30 individuals participated in this study who were being treated for hypertension and were diagnosed with major depression. Escitalopram (10-20 mg) was administered to 15 individuals, while the other 15 received placebo. These individuals were followed for 8 weeks with regular monitoring of blood pressure and heart rate. Scores on the Hamilton Depression Rating Scale were evaluated within the first, second, fourth, and eighth weeks of the study onset.
Results: Comparing with placebo, heart rate was lower in the escitalopram group (66.79 ± 9.85 vs. 74.10 ± 9.52 bpm, p = 0.044). There was not a significant decrease of systolic blood pressure (140.80 ± 16.48 vs 139.61 ± 18.92 mmHg, p = 0.85) and diastolic blood pressure (80.55 ± 12.64 vs 80.18 ± 16.36 mmHg, p = 0.94).
Conclusion: Escitalopram decreases HR, but not BP, in individuals with hypertension and depression. Abbreviation: SH: systemic hypertension; BP: blood pressure; DSM: Diagnostic and Statistical Manual of Mental Disorders; SRQ 20: Self-Report Questionnaire; SCID: Structured Clinical Interview for DSM-IV; HR: heart rate; SNS: Sympathetic nervous system; HPA: hypothalamus-pituitary-adrenal axis; RAA: renin, angiotensin, aldosterone system; NE: norepinephrine; CSF: cerebrospinal fluid; HAM-D: Hamilton Depression Rating Scale; CRF: corticotropin releasing factor; ACTH: adrenocorticotropic hormone; BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; t: time.